Lantern Pharma's LP-184 Shows Promise in Pediatric Brain Cancer Treatment
TL;DR
Lantern Pharma's LP-184 shows promising results in improving survival rates for pediatric brain cancer, potentially revolutionizing treatment.
LP-184 by Lantern Pharma demonstrated significant anti-tumor activity in ATRT subtypes with high blood-brain barrier penetration and a safe profile.
Lantern Pharma's research on LP-184 for pediatric brain cancer offers hope for effective, low-toxicity treatments, aiming to enhance patient outcomes.
LP-184's success in improving survival rates for pediatric brain cancer highlights a potential breakthrough in cancer treatment with promising implications.
Pharmaceutical research firm Lantern Pharma has reported promising preclinical results for LP-184, a potential breakthrough treatment for atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive form of pediatric brain cancer.
Presented by Dr. Eric Raabe of Johns Hopkins at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference, the research revealed dramatic improvements in survival rates across mouse models. In one model, median survival increased by 345%, extending from 20 to 89 days, with statistical significance (p<0.0001).
The experimental drug demonstrated potent anti-tumor activity across ATRT subtypes, with notable characteristics including high blood-brain barrier penetration and a favorable safety profile. ATRT, driven by SMARCB1 gene inactivation, currently lacks effective low-toxicity treatments, making this research potentially transformative for pediatric oncology.
Lantern Pharma plans to launch a pediatric Phase I clinical trial in late 2025 or early 2026, following the completion of its ongoing adult trial and pending consortium approvals. This timeline represents a critical step in potentially developing a targeted therapy for a cancer with historically poor treatment outcomes.
The research underscores the potential of AI-driven drug discovery, with Lantern Pharma leveraging its machine learning platform RADR® to accelerate oncology drug development. The company's approach has enabled rapid progression from initial insights to clinical trials, typically within 2-3 years and at a relatively low cost.
Curated from InvestorBrandNetwork (IBN)